Metagenomi CFO auto-sells 1,911 shares for taxes

Metagenomi Therapeutics’ CFO had shares automatically sold to cover tax withholding from RSU vesting, with over 200,000 shares still held after the transaction.

Rhea-AI Filing Summary

Metagenomi Therapeutics, Inc. (MGX) reported that its Chief Financial Officer, Pamela Wapnick, had 1,911 shares of common stock sold on September 8, 2026 at $1.1584 per share. The company states these shares were automatically sold to satisfy tax withholding obligations upon vesting of restricted stock units and do not represent a volitional trade. Following this transaction, Wapnick directly holds 206,580 shares of common stock.

Insider Trade Summary

Net Seller: 1,911 shares

Net Sell 1 txn

Insider Wapnick Pamela

Role Chief Financial Officer

Sold 1,911 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,911	$1.1584	$2K

Holdings After Transaction: Common Stock — 206,580 shares (Direct)

Footnotes (1)

1. F1. These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person.

Key Figures

Shares sold: 1,911 shares Sale price per share: $1.1584 per share Shares held after transaction: 206,580 shares +2 more

5 metrics

Shares sold 1,911 shares Common stock sold on September 8, 2026 to cover tax withholding

Sale price per share $1.1584 per share Price for the 1,911 shares sold on September 8, 2026

Shares held after transaction 206,580 shares Direct common stock ownership by CFO after the sale

Net shares sold in filing 1,911 shares Net-sell direction across all reported transactions

Transaction date September 8, 2026 Date of the automatic sale for tax withholding

Key Terms

restricted stock units, tax withholding obligations, volitional trade

3 terms

restricted stock units financial

"upon the vesting of certain restricted stock units granted to the Reporting Person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold for the purpose of satisfying the Reporting Person's tax withholding obligations"

volitional trade financial

"and does not represent a volitional trade by the Reporting Person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Metagenomi Therapeutics (MGX) disclose for its CFO?

Metagenomi disclosed that CFO Pamela Wapnick had 1,911 shares of common stock sold on September 8, 2026 at $1.1584 per share, in an automatic transaction tied to tax withholding on vested restricted stock units.

Was the MGX CFO’s September 8, 2026 stock sale a voluntary trade?

No. The company states the 1,911-share sale did not represent a volitional trade by the CFO. The shares were automatically sold to satisfy the CFO’s tax withholding obligations when certain restricted stock units vested.

How many MGX shares does the CFO hold after the reported transaction?

After the September 8, 2026 sale, CFO Pamela Wapnick directly holds 206,580 shares of Metagenomi Therapeutics common stock, according to the filing’s post-transaction ownership figure.

What price was received per share in the MGX CFO’s reported sale?

The 1,911 shares of Metagenomi Therapeutics common stock were sold at an average price of $1.1584 per share, as reported in the Form 4 transaction details.

Why were MGX shares sold in connection with the CFO’s restricted stock units?

The filing explains that the shares were automatically sold to cover the CFO’s tax withholding obligations arising from the vesting of restricted stock units granted on April 1, 2024 and April 1, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 03:35 PM EDT Accepted by SEC EDGAR 09/10/2026 - 03:34 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wapnick Pamela

(Last) (First) (Middle)

C/O METAGENOMI THERAPEUTICS, INC.

5959 HORTON STREET, 7TH FLOOR

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Metagenomi Therapeutics, Inc. [ MGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		S(1)		1,911	D	$1.1584	206,580	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person.

	/s/ Matthew L. Wein, attorney-in-fact	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)